BR112015015474B1 - Sais sulfato de n-(3-(4-(3-(di-isobutilamino)propil) piperazin-1-il)propil)-1h-benzo[d]imidazol-2- amina, seu preparo e uso dos mesmos - Google Patents

Sais sulfato de n-(3-(4-(3-(di-isobutilamino)propil) piperazin-1-il)propil)-1h-benzo[d]imidazol-2- amina, seu preparo e uso dos mesmos Download PDF

Info

Publication number
BR112015015474B1
BR112015015474B1 BR112015015474-3A BR112015015474A BR112015015474B1 BR 112015015474 B1 BR112015015474 B1 BR 112015015474B1 BR 112015015474 A BR112015015474 A BR 112015015474A BR 112015015474 B1 BR112015015474 B1 BR 112015015474B1
Authority
BR
Brazil
Prior art keywords
propyl
disease
piperazin
benzo
imidazol
Prior art date
Application number
BR112015015474-3A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112015015474A2 (enExample
Inventor
Stéphane BURLET
Cécilia ESTRELLA
Mathieu BARRIER
Patricia Melnyk
Nicolas Sergeant
Luc Buee
Philippe Verwaerde
Original Assignee
Alzprotect
Universite De Lille 2 Droit Et Sante
INSERM (Institut National de la Santé et de la Recherche Médicale)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alzprotect, Universite De Lille 2 Droit Et Sante, INSERM (Institut National de la Santé et de la Recherche Médicale) filed Critical Alzprotect
Publication of BR112015015474A2 publication Critical patent/BR112015015474A2/pt
Publication of BR112015015474B1 publication Critical patent/BR112015015474B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112015015474-3A 2012-12-27 2013-12-27 Sais sulfato de n-(3-(4-(3-(di-isobutilamino)propil) piperazin-1-il)propil)-1h-benzo[d]imidazol-2- amina, seu preparo e uso dos mesmos BR112015015474B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12306690.4 2012-12-27
EP12306690 2012-12-27
PCT/EP2013/078068 WO2014102339A1 (en) 2012-12-27 2013-12-27 Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same

Publications (2)

Publication Number Publication Date
BR112015015474A2 BR112015015474A2 (enExample) 2017-08-15
BR112015015474B1 true BR112015015474B1 (pt) 2022-04-19

Family

ID=47501005

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015015474-3A BR112015015474B1 (pt) 2012-12-27 2013-12-27 Sais sulfato de n-(3-(4-(3-(di-isobutilamino)propil) piperazin-1-il)propil)-1h-benzo[d]imidazol-2- amina, seu preparo e uso dos mesmos

Country Status (23)

Country Link
US (3) US9562018B2 (enExample)
EP (1) EP2938597B1 (enExample)
JP (1) JP6384923B2 (enExample)
KR (1) KR102115060B1 (enExample)
CN (1) CN105008333B (enExample)
AU (2) AU2013369288B2 (enExample)
BR (1) BR112015015474B1 (enExample)
CA (1) CA2895285C (enExample)
DK (1) DK2938597T3 (enExample)
ES (1) ES2605494T3 (enExample)
HR (1) HRP20161612T2 (enExample)
HU (1) HUE030930T2 (enExample)
IL (1) IL239450B (enExample)
LT (1) LT2938597T (enExample)
MX (1) MX363367B (enExample)
NZ (1) NZ708959A (enExample)
PL (1) PL2938597T3 (enExample)
PT (1) PT2938597T (enExample)
RS (1) RS55511B1 (enExample)
RU (1) RU2655454C2 (enExample)
SI (1) SI2938597T1 (enExample)
WO (1) WO2014102339A1 (enExample)
ZA (1) ZA201504521B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105008333B (zh) 2012-12-27 2018-02-09 雅尔兹普罗泰特公司 N‑(3‑(4‑(3‑(二异丁基氨基)丙基)哌嗪‑1‑基)丙基)‑1H‑苯并[d]咪唑‑2‑胺的硫酸盐、其制备及其用途
HK1245272B (en) 2015-03-16 2019-09-27 Institut National De La Santé Et De La Recherche Médicale (Inserm) Novel 1,4-bis(3-aminopropyl)piperazine derivative and its use
TWI744300B (zh) * 2016-03-23 2021-11-01 里爾中央醫學中心 改良性熱處理的血小板顆粒裂解液在製備用於治療神經系統疾病的組合物的用途
CN116249693A (zh) * 2020-10-01 2023-06-09 雅尔兹普罗泰特公司 N-(3-(4-(3-(二异丁基氨基)丙基)哌嗪-1-基)丙基)-1H-苯并[d]咪唑-2-胺的琥珀酸盐，其制备及其用途
JP7500875B2 (ja) * 2020-10-07 2024-06-17 アルツプロテクト 運動ニューロン疾患及び神経筋接合部障害の処置のためのｎ－（３－（４－（３－（ジイソブチルアミノ）プロピル）ピペラジン－１－イル）プロピル）－１ｈ－ベンゾ［ｄ］イミダゾール－２－アミン硫酸塩及びそれらの溶媒和物の使用
IL313403A (en) * 2021-12-20 2024-08-01 Alzprotect USE OF N-(3-(4-(3-(DIISOBUTYLAMINO)PROPYL)PIPERAZIN-1-YL)PROPYL)-1H-BENZO[d]IMIDAZOL-2-AMINE SUCCINATE SALTS AND SOLVATES THEREOF FOR THE TREATMENT OF MOTOR NEURON DISEASES AND NEUROMUSCULAR JUNCTION DISORDERS
ES3075524T3 (en) 2022-03-25 2026-08-05 Alzprotect Use of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine salts and solvates thereof for the treatment of sensory neuron diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2674856B1 (fr) * 1991-04-05 1993-07-30 Esteve Labor Dr Nouveaux antihistaminiques non sedatifs, derives de benzimidazole, leur procede de preparation et leur utilisation en tant que medicaments.
JP2001500162A (ja) * 1997-06-12 2001-01-09 トランジェーヌ、ソシエテ、アノニム 少なくとも１種の治療上有効な物質、特にポリヌクレオチド、を標的細胞に導入するための新規脂質複合体および遺伝子治療における使用
CN1325397A (zh) * 1998-09-30 2001-12-05 纽罗根公司 2－哌嗪烷基氨基苯并吡咯衍生物∶多巴胺受体亚型特异配体
WO2002096431A1 (en) * 2001-05-25 2002-12-05 The Regents Of The University Of California Optically active compounds clearing malformed proteins
US20040116441A1 (en) * 2002-10-30 2004-06-17 Pfizer Inc Methods of using sulfonic acid derivatives
CA2509406C (en) * 2002-12-23 2012-07-03 Janssen Pharmaceutica N.V. Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
EP1809288B1 (en) * 2004-11-10 2011-09-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases
CN105008333B (zh) * 2012-12-27 2018-02-09 雅尔兹普罗泰特公司 N‑(3‑(4‑(3‑(二异丁基氨基)丙基)哌嗪‑1‑基)丙基)‑1H‑苯并[d]咪唑‑2‑胺的硫酸盐、其制备及其用途

Also Published As

Publication number Publication date
HUE030930T2 (hu) 2017-06-28
LT2938597T (lt) 2017-01-25
US20190381036A1 (en) 2019-12-19
AU2013369288A8 (en) 2015-07-16
PT2938597T (pt) 2016-12-09
NZ708959A (en) 2019-11-29
RS55511B1 (sr) 2017-05-31
HRP20161612T1 (hr) 2017-01-27
AU2018202218A1 (en) 2018-04-26
US10772884B2 (en) 2020-09-15
AU2013369288B2 (en) 2018-02-22
CN105008333B (zh) 2018-02-09
ES2605494T3 (es) 2017-03-14
AU2013369288A1 (en) 2015-07-02
US10537569B2 (en) 2020-01-21
EP2938597B1 (en) 2016-10-26
KR102115060B1 (ko) 2020-05-25
DK2938597T3 (en) 2017-01-09
BR112015015474A2 (enExample) 2017-08-15
US20170151235A1 (en) 2017-06-01
MX363367B (es) 2019-03-20
HRP20161612T2 (hr) 2017-02-24
HK1215582A1 (en) 2016-09-02
IL239450A0 (en) 2015-07-30
EP2938597A1 (en) 2015-11-04
RU2655454C2 (ru) 2018-05-29
US9562018B2 (en) 2017-02-07
ZA201504521B (en) 2016-11-30
RU2015130671A (ru) 2017-01-30
US20160108003A1 (en) 2016-04-21
CA2895285A1 (en) 2014-07-03
JP2016503813A (ja) 2016-02-08
AU2018202218B2 (en) 2019-02-21
CN105008333A (zh) 2015-10-28
SI2938597T1 (sl) 2017-03-31
WO2014102339A1 (en) 2014-07-03
MX2015008502A (es) 2015-12-16
IL239450B (en) 2018-06-28
KR20150105313A (ko) 2015-09-16
CA2895285C (en) 2021-03-30
JP6384923B2 (ja) 2018-09-05
PL2938597T3 (pl) 2017-03-31

Similar Documents

Publication Publication Date Title
US10772884B2 (en) Sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine, preparation thereof and use of the same
ES2652187T3 (es) Fenilacetato de l-ornitina y métodos para elaborar el mismo
ES2915833T3 (es) Composiciones de isoindolina y métodos para tratar una enfermedad neurodegenerativa y una degeneración macular
ES2746850T3 (es) Formulaciones farmacéuticas que comprenden formas cristalinas de clorhidrato de (R)-7-cloro-N-(quinuclidin-3-il)benzo(b)tiofeno-2-carboxamida monohidratado
TWI540131B (zh) 阿瑞吡坦（ａｐｒｅｐｉｔａｎｔ）ｌ－脯胺酸組成物及共晶體
JP6610793B2 (ja) 環状アミン誘導体の結晶及びその医薬用途
US20230331679A1 (en) Naphthalene monoimide compounds and methods thereof
JP2013529224A (ja) 結晶性エザチオスタット塩酸塩非溶媒和物
US11466008B2 (en) Co-crystals of neflamapimod (VX-745)
JP2019089822A (ja) トピロキソスタットの新規結晶形及びその製造方法
HK1215582B (en) Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same
ES2848436T3 (es) Cristal de derivado de 5-hidroxi-4-(trifluorometil)pirazolopiridina
JP2021527668A (ja) Ｏｇａ阻害化合物
WO2026023672A1 (ja) （２Ｒ）－Ｎ－ベンジル－１－［５－（２－フルオロプロパン－２－イル）－７－オキソ－６，７－ジヒドロ［１，３］チアゾロ［５，４－ｄ］ピリミジン－２－イル］ピロリジン－２－カルボキサミドの新規結晶、およびその製造方法
BR112019005450B1 (pt) Polimorfos cristalinos de um agonista do receptor de acetilcolina muscarínico, processos para preparar tais polimorfos, processo para manter estável um Forma II do polimorfo, composição farmacêutica, processo para preparar medicamento e uso de tais polimorfos
BR122024011971A2 (pt) Polimorfos cristalinos de um agonista do receptor de acetilcolina muscarínico, processos para preparar tais polimorfos, processo para converter a forma i do polimorfo na forma ii do polimorfo, processo para manter estável uma forma ii do polimorfo, composição farmacêutica, processo para preparar medicamento e uso de tais polimorfos
WO2020194260A1 (en) Pharmaceutical salts of benzothiazol compounds, polymorphs and methods for preparation thereof

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25G Requested change of headquarter approved

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) ; ALZPROTECT (FR) ; UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR)

B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/12/2013, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved

Owner name: ALZPROTECT (FR) ; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) ; UNIVERSITE DE LILLE (FR)